Vaxzevria (previously COVID-19 Vaccine AstraZeneca): risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
|
| Active substance |
ChAdOx1-SARS-COV-2
|
| Therapeutic area (MeSH) |
COVID-19 virus infection
|
| Regulatory outcome |
Variation
|
| DHPC type |
Safety signal
|
| Human ATC code |
J07BX03
|
| Dissemination date |
13/10/2021
|